2018 - 2021 Analysis of the resistance mechanisms to molecular-targeting anticancer agents
2015 - 2017 Identification of factors regulating the capacity for both self-renewal and pluripotent differentiation of cancer stem cells and application to cancer treatment.
Papers (102)：
Takahashi M, Okamoto Y, Kato Y, Shirahama H, Tsukahara S, Sugimoto Y, Tomida A. Activating mutations in EGFR and PI3K promote ATF4 induction for NSCLC cell survival during amino acid deprivation. Heliyon. 2023. 9. 4. e14799
Miyazawa M, Yamamoto Y, Katayama K, Sugimoto Y, Noguchi K. Kaposi's sarcoma-associated herpesvirus replication and transcription activator protein activates CD274/PD-L1 gene promoter. Cancer Science. 2023. 114. 4. 1718-1728
Morimoto K, Ishii M, Sugimoto Y, Ogihara T, Tomita M. Inhibitory Effect of Dextran Derivatives on Multidrug Resistance-Related Efflux Transporters in Vitro. Biological and Pharmaceutical Bulletin. 2022. 45. 8. 1036-1042
Adham A.N, Abdelfatah S, Naqishbandi A, Sugimoto Y, Fleischer E, Efferth T. Transcriptomics, molecular docking, and cross-resistance profiling of nobiletin in cancer cells and synergistic interaction with doxorubicin upon SOX5 transfection. Phytomedicine. 2022. 100
Yamatani K, Ai T, Saito K, Suzuki K, Hori A, Kinjo S, Ikeo K, Ruvolo V, Zhang W, Mak PY, et al. Inhibition of BCL2A1 by STAT5 inactivation overcomes resistance to targeted therapies of FLT3-ITD/D835 mutant AML. Translational Oncology. 2022. 18. 101354-101354
Noguchi K, Katayama K, Sugimoto Y. Human ABC transporter ABCG2/BCRP expression in chemoresistance: basic and clinical perspectives for molecular cancer therapeutics. Pharmacogenomics and Personalized Medicine. 2014. 7. 53-64
